EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-SA 4.0

WHY HELICOBACTER PYLORI TREATMENT FAILS IN PAKISTAN? ANTIBIOTIC RESISTANCE AND TRIPLETHERAPY FAILURE: A RAPID SYSTEMATIC REVIEW AND META-ANALYSIS

Dr Ayesha Hanif, Dr Abdul Qadir, Dr Maryam Arshad, Dr Muhammad Bilal Nasir, Dr. Zunaira Muzzamil, Dr Ghias Un Nabi Tayyab, Muhammad Zubair Nazar

Genetics and Molecular Research · 08.06.2026

DOI: 10.4238/0wk27z16 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Genetics and Molecular Research, online erschienen am 08.06.2026. Verfasst von Dr Ayesha Hanif und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Standard triple therapy (a proton-pump inhibitor, clarithromycin and amoxicillin or metronidazole) remains widely used for H. pylori in Pakistan, yet clinicians regularly see patients who are not cured. We asked how common antibiotic resistance is among Pakistani isolates and how often clarithromycin based triple therapy fails.

Methods

We identified Pakistani primary studies through the reference list of a prior South Asian meta analysis and through targeted web searches (17 October 2026). Event counts were extracted by one reviewer. Proportions were pooled on the logit scale with a DerSimonian–Laird random-effects model; we also report Hartung–Knapp–Sidik–Jonkman (HKSJ) intervals, 95% prediction intervals, leave-one-out analyses and an Egger-type test.

Results

Nine unique studies were included (six resistance studies, 656 isolates for clarithromycin; four triple therapy studies, 387 patients). Pooled clarithromycin resistance was 36.3% (95% CI 22.9–52.3; HKSJ 14.3 66.0; I² = 92.5%), with five of six studies above the 15% threshold at which guidelines advise against empirical clarithromycin. Pooled metronidazole resistance was 88.6% (63.4–97.2; k = 4) and fluoroquinolone resistance 35.6% (13.5–66.0; k = 3). Amoxicillin resistance was low but very imprecise (7.5%; 0.7–48.0; k = 3). Clarithromycin-based triple therapy failed in 25.2% of patients (17.8–34.3; HKSJ 14.0–41.0; k = 4). In the one study that linked resistance to outcome, 28 of 30 treatment failures involved clarithromycin-resistant strains.

Conclusions

In the Pakistani data we could retrieve, clarithromycin resistance is well above the guideline threshold, metronidazole resistance is near-universal, and fluoroquinolones are not a safe fallback. These findings support moving away from empirical clarithromycin triple therapy and toward susceptibility-guided or bismuth-based regimens. The evidence base is small, heterogeneous and mostly from Karachi, so the pooled figures should be read as a warning signal rather than a national estimate.

Zitieren

APA

Hanif, D. A., Qadir, D. A., Arshad, D. M., Nasir, D. M. B., Muzzamil, D. Z., Tayyab, D. G. U. N., & Nazar, M. Z. (2026). WHY HELICOBACTER PYLORI TREATMENT FAILS IN PAKISTAN? ANTIBIOTIC RESISTANCE AND TRIPLETHERAPY FAILURE: A RAPID SYSTEMATIC REVIEW AND META-ANALYSIS. Genetics and Molecular Research. https://doi.org/10.4238/0wk27z16

Vancouver

Hanif DA, Qadir DA, Arshad DM, Nasir DMB, Muzzamil DZ, Tayyab DGUN, et al. WHY HELICOBACTER PYLORI TREATMENT FAILS IN PAKISTAN? ANTIBIOTIC RESISTANCE AND TRIPLETHERAPY FAILURE: A RAPID SYSTEMATIC REVIEW AND META-ANALYSIS. Genetics and Molecular Research. 2026. doi:10.4238/0wk27z16

BibTeX
@article{Hanif2026,
  author = {Hanif, Dr Ayesha and Qadir, Dr Abdul and Arshad, Dr Maryam and Nasir, Dr Muhammad Bilal and Muzzamil, Dr. Zunaira and Tayyab, Dr Ghias Un Nabi and Nazar, Muhammad Zubair},
  title = {WHY HELICOBACTER PYLORI TREATMENT FAILS IN PAKISTAN? ANTIBIOTIC RESISTANCE AND TRIPLETHERAPY FAILURE: A RAPID SYSTEMATIC REVIEW AND META-ANALYSIS},
  journal = {Genetics and Molecular Research},
  year = {2026},
  doi = {10.4238/0wk27z16}
}
Kostenlos starten →